Evaxion biotech announces q1 2021 financial results and provides business update

Copenhagen, denmark, may 13, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the first quarter 2021 financial results and provided an operational update.
EVAX Ratings Summary
Quant
EVAX Quant Ranking
Sector
Industry
Quant Rating
Quant Score